Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 16

1.

EORTC SPECTA-AYA: A unique molecular profiling platform for adolescents and young adults with cancer in Europe.

de Rojas T, Kasper B, Van der Graaf W, Pfister SM, Bielle F, Ribalta T, Shenjere P, Preusser M, Fröhling S, Golfinopoulos V, Morfouace M, McCabe MG.

Int J Cancer. 2019 Aug 29. doi: 10.1002/ijc.32651. [Epub ahead of print]

PMID:
31465545
2.

Defining EGFR amplification status for clinical trial inclusion.

French PJ, Eoli M, Sepulveda JM, de Heer I, Kros JM, Walenkamp A, Frenel JS, Franceschi E, Clement PM, Weller M, Ansell P, Looman J, Bain E, Morfouace M, Gorlia T, van den Bent M.

Neuro Oncol. 2019 Oct 9;21(10):1263-1272. doi: 10.1093/neuonc/noz096.

3.

CDK2 inhibitors as candidate therapeutics for cisplatin- and noise-induced hearing loss.

Teitz T, Fang J, Goktug AN, Bonga JD, Diao S, Hazlitt RA, Iconaru L, Morfouace M, Currier D, Zhou Y, Umans RA, Taylor MR, Cheng C, Min J, Freeman B, Peng J, Roussel MF, Kriwacki R, Guy RK, Chen T, Zuo J.

J Exp Med. 2018 Apr 2;215(4):1187-1203. doi: 10.1084/jem.20172246. Epub 2018 Mar 7.

4.

A transatlantic perspective on the integration of immuno-oncology prognostic and predictive biomarkers in innovative clinical trial design.

Morfouace M, Hewitt SM, Salgado R, Hartmann K, Litiere S, Tejpar S, Golfinopoulos V, Lively T, Thurin M, Conley B, Lacombe D.

Semin Cancer Biol. 2018 Oct;52(Pt 2):158-165. doi: 10.1016/j.semcancer.2018.01.003. Epub 2018 Jan 5. Review.

PMID:
29307568
5.

Exploiting a water network to achieve enthalpy-driven, bromodomain-selective BET inhibitors.

Shadrick WR, Slavish PJ, Chai SC, Waddell B, Connelly M, Low JA, Tallant C, Young BM, Bharatham N, Knapp S, Boyd VA, Morfouace M, Roussel MF, Chen T, Lee RE, Kiplin Guy R, Shelat AA, Potter PM.

Bioorg Med Chem. 2018 Jan 1;26(1):25-36. doi: 10.1016/j.bmc.2017.10.042. Epub 2017 Nov 4.

6.

From bench to clinical trials the EORTC experience in biology-based clinical cancer research.

Tryfonidis K, Hartmann K, Morfouace M, Lacombe D.

J Egypt Natl Canc Inst. 2017 Dec;29(4):171-176. doi: 10.1016/j.jnci.2017.09.001. Epub 2017 Nov 6. Review.

7.

Targeting Metabolic Reprogramming by Influenza Infection for Therapeutic Intervention.

Smallwood HS, Duan S, Morfouace M, Rezinciuc S, Shulkin BL, Shelat A, Zink EE, Milasta S, Bajracharya R, Oluwaseum AJ, Roussel MF, Green DR, Pasa-Tolic L, Thomas PG.

Cell Rep. 2017 May 23;19(8):1640-1653. doi: 10.1016/j.celrep.2017.04.039.

8.

Inadequate critical appraisal of studies in systematic reviews of time to diagnosis.

Launay E, Cohen JF, Morfouace M, Gras-Le Guen C, Ravaud P, Chalumeau M.

J Clin Epidemiol. 2016 Oct;78:43-51. doi: 10.1016/j.jclinepi.2016.03.013. Epub 2016 Mar 30. Review.

PMID:
27038853
9.

Preclinical studies of 5-fluoro-2'-deoxycytidine and tetrahydrouridine in pediatric brain tumors.

Morfouace M, Nimmervoll B, Boulos N, Patel YT, Shelat A, Freeman BB 3rd, Robinson GW, Wright K, Gajjar A, Stewart CF, Gilbertson RJ, Roussel MF.

J Neurooncol. 2016 Jan;126(2):225-34. doi: 10.1007/s11060-015-1965-0. Epub 2015 Oct 30.

10.

ABCG2 Transporter Expression Impacts Group 3 Medulloblastoma Response to Chemotherapy.

Morfouace M, Cheepala S, Jackson S, Fukuda Y, Patel YT, Fatima S, Kawauchi D, Shelat AA, Stewart CF, Sorrentino BP, Schuetz JD, Roussel MF.

Cancer Res. 2015 Sep 15;75(18):3879-89. doi: 10.1158/0008-5472.CAN-15-0030. Epub 2015 Jul 21.

11.

Pemetrexed and gemcitabine as combination therapy for the treatment of Group3 medulloblastoma.

Morfouace M, Shelat A, Jacus M, Freeman BB 3rd, Turner D, Robinson S, Zindy F, Wang YD, Finkelstein D, Ayrault O, Bihannic L, Puget S, Li XN, Olson JM, Robinson GW, Guy RK, Stewart CF, Gajjar A, Roussel MF.

Cancer Cell. 2014 Apr 14;25(4):516-29. doi: 10.1016/j.ccr.2014.02.009. Epub 2014 Mar 27.

12.

Control of glioma cell death and differentiation by PKM2-Oct4 interaction.

Morfouace M, Lalier L, Oliver L, Cheray M, Pecqueur C, Cartron PF, Vallette FM.

Cell Death Dis. 2014 Jan 30;5:e1036. doi: 10.1038/cddis.2013.561.

13.

Deriving therapies for children with primary CNS tumors using pharmacokinetic modeling and simulation of cerebral microdialysis data.

Jacus MO, Throm SL, Turner DC, Patel YT, Freeman BB 3rd, Morfouace M, Boulos N, Stewart CF.

Eur J Pharm Sci. 2014 Jun 16;57:41-7. doi: 10.1016/j.ejps.2013.11.010. Epub 2013 Nov 20. Review.

14.

Quality of reporting of studies evaluating time to diagnosis: a systematic review in paediatrics.

Launay E, Morfouace M, Deneux-Tharaux C, Gras le-Guen C, Ravaud P, Chalumeau M.

Arch Dis Child. 2014 Mar;99(3):244-50. doi: 10.1136/archdischild-2013-304778. Epub 2013 Nov 21. Review.

PMID:
24265414
15.

Delays in diagnosis of paediatric cancers: a systematic review and comparison with expert testimony in lawsuits.

Brasme JF, Morfouace M, Grill J, Martinot A, Amalberti R, Bons-Letouzey C, Chalumeau M.

Lancet Oncol. 2012 Oct;13(10):e445-59. doi: 10.1016/S1470-2045(12)70361-3. Review.

PMID:
23026830
16.

Comparison of spheroids formed by rat glioma stem cells and neural stem cells reveals differences in glucose metabolism and promising therapeutic applications.

Morfouace M, Lalier L, Bahut M, Bonnamain V, Naveilhan P, Guette C, Oliver L, Gueguen N, Reynier P, Vallette FM.

J Biol Chem. 2012 Sep 28;287(40):33664-74. Epub 2012 Jul 10.

Supplemental Content

Loading ...
Support Center